Minerva Surgical (UTRS) 10-Q 3 May 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	Apr. 25, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Trading Symbol	UTRS
Title of 12(b) Security	Common Stock, $ 0.001 par value
Security Exchange Name	NASDAQ
Entity Registrant Name	MINERVA SURGICAL, INC.
Entity Central Index Key	0001452965
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		176,842,499
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40919
Entity Tax Identification Number	26-3422906
Entity Address, Address Line One	4255 Burton Dr.
Entity Address, City or Town	Santa Clara
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054
City Area Code	855
Local Phone Number	646-7874
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 25,255	$ 6,942
Restricted cash, current	604	604
Accounts receivable, net	7,392	7,244
Inventory	17,195	16,850
Prepaid expenses and other current assets	3,665	4,479
Total current assets	54,111	36,119
Restricted cash, net of current portion	265	265
Intangible asset, net	24,733	26,778
Property and equipment, net	5,375	5,042
Operating lease right-of-use asset	109	270
Other non-current assets	575	426
Total assets	85,168	68,900
Current liabilities:
Accounts payable	3,690	2,804
Accrued compensation	3,142	3,701
Accrued liabilities	4,723	5,524
Operating lease liability	143	355
Current portion of long-term debt	5,139	1,894
Total current liabilities	16,837	14,278
Long-term debt	34,260	37,441
Total liabilities	51,097	51,719
Commitments and contingencies (Note 8)
Stockholders’ deficit:
Preferred stock, $0.001 par value,15,000,000 and 5,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value, 300,000,000 and 100,000,000 shares authorized, and 176,800,219 shares and 29,816,161 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	176	29
Additional paid-in capital	328,740	300,809
Accumulated other comprehensive income	11	11
Accumulated deficit	(294,856)	(283,668)
Total stockholders' equity	34,071	17,181
Total liabilities and stockholders equity	$ 85,168	$ 68,900

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	15,000,000	5,000,000
Preferred stock, shares, Issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	100,000,000
Common stock, shares, Issued	176,800,219	29,816,161
Common stock, shares, outstanding	176,800,219	29,816,161

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenues	$ 12,533	$ 10,935
Cost of goods sold	5,518	5,522
Gross profit	7,015	5,413
Operating expenses
Sales and marketing	10,202	9,473
General and administrative	5,358	4,985
Research and development	1,765	1,255
Total operating expenses	17,325	15,713
Loss from operations	(10,310)	(10,300)
Interest income	38	9
Interest expense (includes $nil and $4.5 million to related parties in years ended December 31, 2022 and 2021, respectively)	(1,068)	(632)
Other expense, net	(3)	(2)
Net loss before income taxes	(11,343)	(10,925)
Income tax expense	0	0
Net Loss	$ (11,343)	$ (10,925)
Net loss per share attributable to common stockholders, basic	$ (0.12)	$ (0.38)
Net loss per share attributable to common stockholders, diluted	$ (0.12)	$ (0.38)
Weighted-average shares used in computing net loss per share, basic and diluted	96,573,894	28,480,745

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect Period Of Adoption Adjustment	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Accumulated Deficit Cumulative Effect Period Of Adoption Adjustment
Balance at Dec. 31, 2021	$ 44,104		$ 28	$ 293,621	$ 11	$ (249,556)
Balance, shares at Dec. 31, 2021			28,822,283
Issuance of common stock upon exercise of stock options	3			3
Issuance of common stock upon exercise of stock options, shares			5,166
Vesting of early exercised stock options	39			39
Stock-based compensation expense	1,523			1,523
Net loss	(10,925)					(10,925)
Balance at Mar. 31, 2022	34,744		$ 28	295,186	11	(260,481)
Balance, shares at Mar. 31, 2022			28,827,449
Balance at Dec. 31, 2022	17,181	$ 155	$ 29	300,809	11	(283,668)	$ 155
Balance, shares at Dec. 31, 2022			29,816,161
Accounting Standards Update [Extensible List]		ASU 2016 -13					ASU 2016 -13
Proceeds from issuance of common stock, Share Purchase Agreement, net	$ 26,774		$ 147	26,627
Proceeds from issuance of common stock, Share Purchase Agreement, net, shares			146,627,565
Issuance of common stock upon release of RSUs, shares			356,487
Issuance of common stock upon exercise of stock options, shares	6		6
Vesting of early exercised stock options	$ 30			30
Stock-based compensation expense	1,274			1,274
Net loss	(11,343)					(11,343)
Balance at Mar. 31, 2023	$ 34,071		$ 176	$ 328,740	$ 11	$ (294,856)
Balance, shares at Mar. 31, 2023			176,800,219

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flows From Operating Activities:
Net loss	$ (11,343)	$ (10,925)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and debt issuance costs	64	61
Depreciation and amortization	2,514	2,668
Non-cash lease expense	161	153
Stock-based compensation expense	1,274	1,523
Change in fair value of contingent consideration liability		(151)
Property and equipment write-downs/disposals		10
Net changes in operating assets and liabilities:
Accounts receivable, net	7	142
Inventory	(1,128)	(1,127)
Prepaid expenses and other current assets	814	997
Other non-current assets	(149)
Accounts payable	942	(550)
Accrued liabilities	(771)	402
Accrued compensation	(559)	(631)
Operating lease liability	(212)	(197)
Net cash used in operating activities	(8,386)	(7,625)
Cash Flows From Investing Activities:
Purchase of property and equipment	(75)	(82)
Net cash used in investing activities	(75)	(82)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock under Share Purchase Agreement, net	26,774
Payment of contingent consideration		(5,000)
Proceeds from issuance of common stock		3
Net cash (used in) provided by financing activities	26,774	(4,997)
Net increase (decrease) in cash, cash equivalents and restricted cash	18,313	(12,704)
Cash, cash equivalents and restricted cash at the beginning of the period	7,811	48,415
Cash, cash equivalents and restricted cash at the end of the period	26,124	35,711
Reconciliation of cash, cash equivalents and restricted cash to balance sheets
Cash and cash equivalents	25,255	27,904
Restricted cash	869	7,807
Cash, cash equivalents and restricted cash in balance sheets	26,124	35,711
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	986	568
Supplemental Disclosure of Non-cash Items:
Vesting of early exercised stock options	30	39
Purchases of property and equipment included in accounts payable		18
Net reclassification of inventory to property and equipment for customer usage agreements	783	805
Cummulative effect adjustment from adoption of ASU 2016-13	$ 155
Right of use asset acquired under operating lease on the adoption of ASC 842		$ 894

Formation and Business of the C

Formation and Business of the Company	3 Months Ended
	Mar. 31, 2023
Disclosure Text Block [Abstract]
Formation and Business of the Company	1. Formation and Business of the Company The Company Minerva Surgical, Inc. (the Company, we, us, and our) was incorporated in the state of Delaware on November 3, 2008. The Company's headquarters are in Santa Clara, California. The Company is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company commenced commercial introduction of its products in the United States in 2015 following the clearance by the U.S. Food and Drug Administration (FDA). In May 2020, the Company acquired certain assets from Boston Scientific Corporation (BSC) to broaden its product offerings to its customers. The Company derives all of its revenue from sales to customers in the United States through a direct sales force. Private Placement On December 27, 2022, the Company entered into a Share Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with Accelmed Partners II L.P. (“Accelmed”) and New Enterprise Associates 13, L.P. (each, a “Purchaser,” and collectively, the “Purchasers”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers an aggregate of 146,627,565 shares (the “Shares”) of the Company’s common stock, par value $ 0.001 per share, at a purchase price of $ 0.2046 per Share, which represented a 25 % premium to the trailing five-day volume-weighted average price of the Company’s common stock on December 23, 2022. On February 9, 2023, the Private Placement closed, and the Company issued the Shares to the Purchasers, resulting in aggregate gross proceeds to the Company of $ 30.0 million before deducting placement agent fees and estimated offering expenses of $ 3.2 million. Liquidity In accordance with Financial Accounting Standard Board (FASB) Accounting Standards Codification (ASC) 205-40, Presentation of Financial Statements – Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved before the date that the financial statements are issued. The Company’s financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company incurred a net loss of $ 11.3 million during the three months ended March 31, 2023 and had an accumulated deficit of $ 294.9 million as of March 31, 2023. T he Company had cash and cash equivalents of $ 25.3 million as of March 31, 2023. The Company prepared an internal forecast that includes alternatives to refinance its outstanding term loan and to potentially raise additional capital as needed over the next twelve months. Under the current terms of the outstanding term loan, the Company will be required to begin repaying the principal balance starting November 2023, the end of the interest only period. Should the Company fail to refinance the CIBC Agreement or raise additional capital, the latest forecast represents the possibility that its cash and cash equivalents will not be sufficient to fund the Company's operations within the next twelve months. As of March 31, 2023, the Company was in compliance with the financial covenants required by its Loan and Security Agreement with Canadian Imperial Bank of Commerce (the CIBC Agreement). However, the inherent uncertainties described above may impact the Company’s ability to remain in compliance with these covenants over the next twelve months. A potential financial covenant violation, should it occur, would put the company in technical default per the terms of the CIBC Agreement and provide for remedies to the bank per that agreement. These circumstances impact the Company's ability to fund its current business plan within the twelve months from the date of issuance of these financial statements. The presence of these conditions, individually or in the aggregate, raises substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is considering raising additional capital through debt, equity or a combination financing in the future. However, such additional financings may not be available on acceptable terms, or at all. If the Company is unable obtain adequate financing on acceptable terms, it may terminate or delay the development of one or more of its products, delay sales and marketing efforts or other activities necessary to commercialize its products or modify its operations to operate within available resources. Failure to manage discretionary spending or raise additional financing as needed, may adversely impact its ability to achieve its intended business objectives. While the Company believes its plans will alleviate the conditions that raise substantial doubt, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring. Impact of the COVID-19 pandemic The COVID-19 pandemic and the resulting economic downturn have impacted business conditions in the industry in which the Company operates. Since March 2020, the Company’s net sales were negatively impacted by the COVID-19 pandemic as hospitals and ambulatory surgical centers (ASCs) delayed or canceled elective procedures. In response to the pandemic, many state and local governments in the U.S. issued orders that temporarily precluded elective procedures in order to conserve scarce health system resources. The decrease in hospital and ASCs admission rates and elective surgeries reduced both the number of patients being evaluated for treatment with and demand for elective procedures using the Company's products. More recently, we have seen the impacts from COVID-19 lessening with hospitals and ASCs returning to more normal operations and supply chain disruptions becoming less frequent. The staffing impacts on hospitals may continue for some time but the elimination of elective procedures has been diminishing. The ultimate extent of the impact of the COVID-19 pandemic on the Company is highly uncertain and subject to change. This impact may result in a material, adverse impact on liquidity, capital resources, supply chain, operations and revenue and may affect third parties on which the Company relies.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (GAAP). Certain prior year amounts have been reclassified to conform to the current year presentation. Unaudited interim financial information The accompanying condensed balance sheet as of March 31, 2023, the condensed statements of operations, the condensed statements of stockholders’ equity and condensed statements of cash flows for the periods ended March 31, 2023 and 2022 are unaudited. The unaudited interim condensed financial statements have been prepared on the same basis as the 2022 audited annual financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2023 and the results of its operations and its cash flows for the three-month periods ended March 31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three-month periods ended March 31, 2023 and 2022 are also unaudited. The results for the three-month period ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods, or any future year or period. The balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. Certain disclosures have been condensed or omitted from the interim condensed financial statements. These unaudited interim condensed financial statements should be read in conjunction with the audited annual financial statements and related notes. The significant accounting policies used in the preparation of the unaudited condensed financial statements for the three-month periods ended March 31, 2023 and 2022, are consistent with those discussed in Note 2 to the audited financial statements and notes thereto for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC) on March 22, 2023. There have been no significant changes in the significant accounting policies or critical accounting estimates since December 31, 2022, except for the accounting policy related to FASB Accounting Standards Update (ASU) 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments discussed below. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Significant estimates and assumptions include accounts receivable allowances, inventory allowances, recoverability of long-term assets, including definite-lived intangible assets, revaluation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, contingent consideration liability, valuation of the redeemable convertible preferred stock warrant liability and derivative liabilities, deferred tax assets and related valuation allowances, impact of contingencies and the Company’s incremental borrowing rate used to calculate lease assets . Change in accounting estimate In accordance with our policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis. This review, which included a study of historic replacement requirements, indicated that the actual lives of equipment under customer usage agreements were longer than the estimated useful lives used for depreciation purposes. As a result, effective January 1, 2023, the Company changed its estimate of the useful lives of equipment under customer usage agreements from three to five years . The effect of this change in estimate was to reduce depreciation expense by $ 0.3 million, decrease net loss by $ 0.3 million and decrease basic and diluted loss per share by an immaterial amount, for the three months ended March 31, 2023. Fair value of financial instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their fair value due to the short-term nature of these assets and liabilities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates its fair value and is classified as a Level 2 liability. Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (FDIC) insured limits. The Company earns revenue from sale of disposable devices and controllers to customers such as hospitals, ambulatory surgical centers and physician offices. The Company’s accounts receivable are derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral from its customers. At March 31, 2023 and 2022, and for the periods then ended, no customer accounted for more than 10.0% of accounts receivable or revenue. Concentration of suppliers The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect our results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event. Accounts Receivable and Estimated Credit Losses The Company adopted ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , effective January 1, 2023 using the modified retrospective method. The adoption of this standard did not have a material cumulative effect on opening accumulated deficit as of January 1, 2023 and did not have a material impact on the Company’s financial statements for the three months ended March 31, 2023. As of January 1, 2023, accounts receivable are recorded at invoice value, net of the Company's reserve for estimated credit losses. The Company applies its loss-rate method to measure its estimated credit loss for receivables using its historical collection experience, current and ongoing evaluation of customer balances including transaction history, aging status and financial condition of its customers, plus reasonable and supportable forecast of future economic market conditions. Specific credit loss reserve amounts are established to record the appropriate reserve for the Company's current estimate of credit losses (CECL) reserves for its pool of identified customers that have an identified risk of default. A general credit loss reserve is then established based upon the Company’s assessment of estimated credit losses for its remaining receivables pool based on its loss-rate method. Balances are written-off when they are ultimately determined to be uncollectible. The following table summarizes the activity in the reserve for credit loss account (in thousands): January 1, 2023 $ 542 Amounts charged (reversed) to costs and expenses ( 1 ) Write-offs ( 26 ) March 31, 2023 $ 515 Advertising costs Expenses related to advertising of products are charged to sales and marketing expense as incurred. During the three months ended March 31, 2023, the Company incurred $ 0.1 million in advertising expenses. The Company did no t have any material advertising expenses during the three months ended March 31, 2022. Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, , redeemable convertible preferred stock warrants, convertible notes, common stock subject to repurchase, restricted stock units and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss per share is presented. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. Because the Company has reported a net loss for the three-month periods ended March 31, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for all periods presented.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements The Company adopted ASU 2016-3, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13) effective Ja nuary 1, 2023 , using the modified retrospective approach with a cumulative effect adjustment to the accumulated deficit at the beginning of the period of adoption . Upon adoption of ASU 2016-13 , the Company derecognized its allowance for doubtful accounts of $ 0.7 million, recognized a CECL reserve of $ 0.5 million with a net adjustment to retained earnings of $ 0.2 million as of January 1, 2023 with no resulting impact to the condensed statements of operations or condensed statements of cash flows.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue	4. Revenue Disaggregation of revenue For the Three Months Ended March 31, 2023 2022 Minerva ES 45.2 % 44.0 % Genesys HTA 27.8 % 30.3 % Symphion 26.3 % 25.1 % Other 0.7 % 0.6 % 100.0 % 100 % For the three months ended March 31, 2023 and 2022, approximately 100 % and 99.4 % of the Company’s revenue is subject to point-in-time recognition for single-use (disposable) products and capital equipment across all revenue streams. Sale of extended warranties on capital equipment within other revenue represents 0.1 % a nd less than 1.0 % of the Company’s revenue for the three-m onth periods ended on March 31, 2023 and 2022. In addition, for the three months ended March 31, 2023 and 2022, 98.3 % an d 97.0 % of the Company’s total revenue is derived from the sale of single-use (disposable) products; therefore, the Company did not include disaggregated revenue data to present the amounts attributed to capital equipment, associated warranties, and miscellaneous revenue separately. Contract balances The Compan y’s contract balances consist of the following (in thousands): March 31, December 31, 2023 2022 Accounts receivable, net $ 7,392 $ 7,244 Contract liability—current (see Note 6) $ 581 $ 339

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair value measurements	5. Fair value measurements ASC 820, Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described below: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3—Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis —Financial assets held by the Company measured at fair value on a recurring basis include money market funds which are classified as Level 1 within the fair value hierarchy as the inputs used to measure fair value are quoted prices in active markets for identical assets. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Fair value of assets and liabilities The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): March 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 20,687 $ — $ — $ 20,687 Total financial assets $ 20,687 $ — $ — $ 20,687 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 3,149 $ — $ — $ 3,149 Total financial assets $ 3,149 $ — $ — $ 3,149 The change in fair value of the contingent consideration liability is summarized below (in thousands): Contingent Fair value, December 31, 2021 $ 14,094 Change in fair value ( 151 ) Payment ( 5,000 ) Ending fair value, March 31, 2022 $ 8,943 As of December 31, 2022, the contingent consideration liability due to BSC for the potential future milestone payment was resolved and a liability was no longer recorded.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2023
Balance Sheet Components [Abstract]
Balance Sheet Components	6. Balance Sheet Components Cash and cash equivalents The Company’s cash and cash equivalents consist of the following (in thousands): March 31, December 31, 2023 2022 Cash $ 4,568 $ 3,793 Cash equivalents: Money market funds 20,687 3,149 Total cash and cash equivalents $ 25,255 $ 6,942 Inventory Inventory consists of the following (in thousands): March 31, December 31, 2023 2022 Finished goods $ 7,295 $ 7,142 Component materials 9,900 9,708 Total inventory $ 17,195 $ 16,850 Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, 2023 2022 Prepaid expenses $ 2,465 $ 2,164 Prepaid insurance 1,009 1,560 Other current assets 191 755 Total prepaid expenses and other current assets $ 3,665 $ 4,479 Property and equipment, net Property and equipment, net consist of th e following (in thousands): March 31, December 31, Useful life (years) 2023 2022 Computers and software 2 $ 398 $ 343 Machinery and equipment 3 667 664 Furniture and fixtures 7 48 48 Tools and dies 2 901 900 Construction in progress — 88 131 Equipment under customer usage agreements 5 13,733 13,226 Leasehold improvements Lesser of useful life or lease term 155 155 15,990 15,467 Less: accumulated depreciation and amortization ( 10,615 ) ( 10,425 ) Property and equipment, net $ 5,375 $ 5,042 Depreciation and amortization expense on property and equipment was $ 0.5 million and $ 0.6 million for the three-month periods ended on March 31, 2023 and 2022, respectively. Of this amount $ 0.4 million and $ 0.6 million for the three-month periods ended on March 31, 2023 and 2022, respectively, was related to equipment under customer usage agreements recorded to cost of goods sold, which reflects a change in estimate of $ 0.3 million reducing depreciation expense recognized during the three-month period ended March 31, 2023. See Note 2 for further information. Intangible asset, net Intangible asset, net con sist of the following (in thousands): March 31, 2023 Remaining life (years) Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks 3.7 $ 3,969 $ ( 1,756 ) $ 2,213 Developed technology 0.2 30,819 ( 8,860 ) 21,959 Customer relationships 7.2 13,466 ( 12,905 ) 561 Total intangible assets $ 48,254 $ ( 23,521 ) $ 24,733 December 31, 2022 Remaining life (years) Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks 3.9 $ 3,969 $ ( 1,603 ) $ 2,366 Developed technology 0.4 30,819 ( 8,090 ) 22,729 Customer relationships 7.4 13,466 ( 11,783 ) 1,683 Total intangible assets $ 48,254 $ ( 21,476 ) $ 26,778 Amortization expense on intangible assets was $ 2.0 million for the three-month periods ended on March 31, 2023 and 2022. Future amortization expense of intangible assets related to the acquisition of assets from Boston Scientific Corporation (BSC) as of March 31, 2023 is as follows (in thousands): 2023 (remaining nine months) $ 3,331 2024 3,693 2025 3,693 2026 3,614 2027 3,082 Thereafter 7,320 Total $ 24,733 Accrued compensation Accrued compensation consists of the following (in thousands): March 31, December 31, 2023 2022 Accrued vacation $ 1,550 $ 1,559 Accrued bonuses 651 1,248 Accrued commissions 843 730 Other accrued personnel related expenses 98 164 Total accrued compensation $ 3,142 $ 3,701 Accrued liabilities Accrued liabilities consist of the following (in th ousands): March 31, December 31, 2023 2022 Accrual for litigation $ 2,000 $ 2,000 Accrued professional fees 400 643 Accrued sales and use taxes 339 271 Accrual for inventory in transit - 663 Contract liability 581 339 Accrued interest expense 339 321 Others 1,064 1,287 Total accrued liabilities $ 4,723 $ 5,524 As of March 31, 2023, inventory in transit of $ 0.7 million had been invoiced and recognized into accounts payable.

Debt

Debt	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt	7. Debt CIBC term loan On October 8, 2021, the Canadian Imperial Bank of Commerce (CIBC) and the Company entered into a Loan and Security Agreement (the CIBC Agreement), which provides for a senior secured term loan in an aggregate principal amount of $ 40.0 million (the CIBC Loan), the full amount of which was funded at the closing of the CIBC Agreement. The CIBC Loan provides for 24 months of interest-only payments followed by 36 equal monthly payments of principal, plus accrued and unpaid interest, with the final obligations due and payable in full on October 8, 2026. The CIBC Loan accrues interest at a floating rate equal to 2.5% above the prime rate, and the interest is payable monthly in arrears. As of March 31, 2023, the CIBC Loan had an annual effective interest rate of 11.9 % per annum. T he Company may prepay the CIBC Loan in whole or in parts. Obligations under the CIBC Agreement are secured by substantially all of the Company’s assets. The CIBC Agreement contains customary affirmative and negative covenants as well as financial covenants that require the Company to maintain minimum revenue and minimum cash thresholds. The CIBC Agreement contains customary events of default subject to customary cure periods for certain defaults that include, among others, non-payment defaults, inaccuracy of representations and warranties, covenant defaults, cross-defaults to certain other material indebtedness, bankruptcy, and insolvency events with respect to the Company, and material judgements. Upon the occurrence and during the continuance of an event of default, CIBC may accelerate the Company’s obligations under the CIBC Agreement, increase the applicable interest rate by 5.0% and exercise other remedies provided for under the CIBC Agreement and applicable law. The CIBC Loan consists of the following (in thousands): March 31, December 31, 2023 2022 Term loan principal $ 40,000 $ 40,000 Less: Debt discount and debt issuance cost ( 601 ) ( 665 ) Accrued interest 339 321 Term loan $ 39,738 $ 39,656 The Company paid $ 1.0 million in fees to CIBC and third parties which is reflected as a debt discount and debt issuance costs, respectively, and are being accreted over the life of the term loan using the effective interest method. During the three-month periods ended March 31, 2023 and 2022, the Company recorded interest expen se of $ 1.1 million a nd $ 0.6 million, which include interest expense related to accretion of debt discount and debt issuance costs of the CIBC Loan of $ 0.1 million , respectively. Contractual maturities of financing obligations As of March 31, 2023, the aggregate future payments under the CIBC Loan (including interest payments) are as follows (in thousands): 2023 (remaining nine months) $ 5,650 2024 16,323 2025 14,958 2026 12,508 Total 49,439 Less: unamortized debt discounts and issuance costs ( 601 ) Less: interest ( 9,100 ) Term loan $ 39,738

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating lease The Company's corporate headquarters, research and development facilities, manufacturing and distribution center are located in Santa Clara, CA (Santa Clara facility) and are subject to a non-cancellable operating sublease that terminates in May 2023. On July 29, 2022, the Company entered into a new operating lease arrangement (Mission Park Lease) for its current Santa Clara facility. The new lease commences on June 1, 2023 and will expire on May 31, 2028 and contains monthly base rent payments of approximately $ 88,341 that increase annually by 3 % over the term of the lease. In addition to the base rent, the Company will reimburse the landlord for certain operating expenses under the terms of the new lease. The Company established a letter of credit for $ 0.3 million as collateral for the Mission Park Lease in favor of the new lessor and it is recorded as restricted cash on the balance sheet. The Company recognized rent expense on the Santa Clara facility of $ 0.2 million for each of the three-month periods ended on March 31, 2023 and 2022. The Company adopted ASC 842 and the related amendments on January 1, 2022 . The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the three -month periods ended March 31, 2023 and 2022: For Three Months Ended Lease Cost (in thousands) Operating lease cost $ 163 Variable lease cost — Total lease cost $ 163 Other Information Operating cash flows used for lease liabilities $ 212 Right of use asset acquired under operating lease on the adoption of ASC 842 $ 109 Weighted average remaining lease term (in years) 0.2 Weighted average incremental borrowing rate 4.0 % As of March 31, 2023, operating lease right of use assets were $ 0.1 million and operating lease liabilities were $ 0.1 million. T he Company has no finance leases. The maturities of the operating lease liabilities were as follows (in thousands): March 31, 2023 2023 minimum payments $ 143 Total undiscounted lease payments 143 Less: imputed interest — Total operating lease liability, current maturities $ 143 The future minimum lease payments under all non-cancelable operating lease obligations as of March 31, 2023 were as follows (in thousands): 2023 (remaining two months) $ 143 Total minimum lease payments $ 143 The Company maintains letters of credit of $ 0.5 million in connection with the Company’s Santa Clara Lease. As of March 31, 2023 and December 31, 2022, the cash amount associated with the Santa Clara Lease is recorded as restricted cash on the balance sheet. Indemnification The Company enters into indemnification provisions under its agreements with other companies in the ordinary course of business, including business partners and contractors. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party as a result of the Company’s activities. The terms of these indemnification agreements are generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. The Company maintains commercial general liability insurance and products liability insurance to offset certain of its potential liabilities under these indemnification provisions. Litigation The Company regularly evaluates its exposure to threatened or pending litigation and other business contingencies. Because of the uncertainties related to the amount of loss from litigation and other business contingencies, the recording of losses relating to such exposures requires significant judgment about the potential range of outcomes. As additional information about current or future litigation or other contingencies becomes available, the Company will assess whether such information warrants the recording of additional expense. Second Hologic Action On July 8, 2020, Hologic sued the Company alleging willful infringement of one of the same patents as in the First Action, the ’348 patent, in the U.S. District Court for the District of Delaware. Hologic accused the Company’s newer EAS Handpiece of infringing the patent for the approximately five-month period before that patent expired on November 19, 2018. The Company has answered, denying infringement and willfulness. Due to COVID-19 and the on-going appeal of the First Hologic Action at the time, the case was stayed twice. In late 2022, the court lifted the stay and has scheduled trial for August 21, 2023. As of March 31, 2023, the Company recognized a legal accrual which represents management’s best estimate of the potential loss from this litigation. First Minerva Action In April 2017, the Company sued Hologic for willful infringement of a Company patent (U.S. Patent No. 9,186,208 (“the ’208 patent”)) in the U.S. District Court for the Northern District of California. Hologic has answered, denying infringement and willfulness and alleging invalidity of the patent. The Company sought a preliminary injunction and that motion was denied. This matter was thereafter transferred to the U.S. District Court for the District of Delaware, where it has been assigned to the same judge presiding over the Hologic complaints. Due to COVID-19, the July 2020 trial date was delayed. On July 20, 2021, the District Court granted Hologic’s motion excluding certain expert opinions regarding infringement. On July 23, 2021, the District Court found on summary judgment that the Company’s ’208 patent is invalid, dismissed the case and entered judgment. On August 24, 2021, the Company appealed to the Court of Appeals for the Federal Circuit. Briefing was completed and oral argument in the matter was held on October 3, 2022. On February 14, 2023 a three judge panel upheld the lower court’s ruling and denied the Company’s request for a hearing. The Company has decided not to pursue this claim furth er.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The Company did no t record an income tax provision for the three-month periods ended March 31, 2023 and 2022. The Company’s net deferred tax assets are fully offset by a valuation allowance, as the Company believes it is more likely than not the benefit will not be realized.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Preferred stock The Amended and Restated Certificate of Incorporation authorizes the Company to issue up to 15,000,000 shares of $ 0.001 par value preferred stock. Common stock The Amended and Restated Certificate of Incorporation authorizes the Company to issue up t o 300,000,000 shares of $ 0.001 par value common stock. Private Placement On December 27, 2022, the Company entered into a Purchase Agreement and agreed to sell an aggregate of 146,627,565 shares of the Company’s common stock. On February 9, 2023, the Private Placement closed and the Company issued the shares. Common stock warrants As of March 31, 2023, the Company`s outstanding warrants to purchase shares of common stock, consisted of the following: Issuance Date Number of Shares of Common Stock Issuable Exercise Price Classification Expiration Date May 9, 2017 33,964 $ 11.31 Equity May 8, 2027 July 19, 2019 43,878 $ 11.31 Equity July 18, 2029 77,842 Shares reserved for future issuance The Company has shares of common stock reserved for future issuances as follows: March 31, December 31, 2023 2022 Warrants to purchase common stock 77,842 77,842 Common stock options issued and outstanding 27,056,747 2,290,596 Common stock available for future grants 13,557,722 374,099 Restricted stock units issued and outstanding 871,792 1,247,059 Common stock available for ESPP 3,541,141 62 2008 Stock Plan and 2021 Equity Incentive Plan, as amended (the 2021 and 2008 Plan) A summar y of stock option activity is set forth below (in thousands, except share and per share data): Number of Weighted Weighted Aggregate Outstanding, December 31, 2022 2,290,596 $ 8.33 8.0 $ 1 Options granted 24,921,277 $ 0.28 Options exercised ( 6 ) $ 0.61 Options forfeited or cancelled ( 155,120 ) $ 7.32 Outstanding, March 31, 2023 27,056,747 $ 0.92 9.7 $ 1 Shares exercisable March 31, 2023 1,506,339 $ 8.86 6.0 $ - Vested and expected to vest, March 31, 2023 27,056,747 $ 0.92 9.7 $ 1 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money as of March 31, 2023 and December 31, 2021. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 was de minimis. The total fair value of options that vested during the three months ended March 31, 2023 and 2022 was $ 0.8 million and $ 1.0 million, respectively. The options granted during the three months ended March 31, 2023 and 2022 had a weighted-average per share grant-date fair value o f $ 0.20 per share and $ 3.50 per share, respectively. As of March 31, 2023, the total unrecognized stock-based compensation expense related to unvested stock options wa s $ 8.6 million, which is expected to be recognized over the remaining weighted-average vesting period o f 3.3 years. Early exercise of stock options The terms of the 2008 Plan permit the exercise of certain options granted under the 2008 Plan prior to vesting, subject to required approvals. The shares are subject to the Company’s lapsing repurchase right upon termination of employment at the original purchase price. The proceeds initially are recorded in accrued current liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses. During the three months ended March 31, 2023 and 2022, the Company had no repurchases of common stock. As of March 31, 2023 and December 31, 2022, there were 140,413 shares and 188,025 shares that were subject to repurchase, respectively. The aggregate exercise prices of early exercised shares as of March 31, 2023 and December 31, 2022 were $ 0.1 million and $ 0.1 million, respe ctively, which were recorded in other current liabilities on the balance sheets. Restricted Stock Units A summary of RSU activity is s et forth below: Number of Weighted Average Grant Date Fair Value Unvested, December 31, 2022 1,247,059 $ 2.58 Released ( 356,487 ) $ 2.58 Forfeited or cancelled ( 18,780 ) $ 2.63 Unvested, March 31, 2023 871,792 $ 2.58 As of March 31, 2023, the total unrecognized stock-based compensation expense related to unvested restrict ed stock units was $ 1.7 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.8 years. 2021 Employee Stock Purchase Plan, as amended (ESPP) The fair value of the predicted share purchase rights granted under the ESPP upon the commencement of the offering period was estimated on the date of grant using the Black-Scholes option pricing model applying the following assumptions as of December 1, 2022, the current offering period's commencement date: (i) risk- free interest rate 4.61 %, (ii) dividend rate 0 %, (iii) expected terms 0.5 year and 1.0 year, and (iv) volatility 77.21 % and 76.29 %, for the two tranches, respectively. Compensation expe nse of less than $ 0.1 million wa s recorded into the condensed statement of operations for the three-months ended March 31, 2023. As of March 31, 2023, the total unrecognized compensation cost related to the ESPP tranches was immaterial, which will be amortized for the two tranches over weighted-average periods of approxi mately 0.5 years. Stock-based compensation associated with awards to employees and non-employees Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended March 31, 2023 2022 Cost of goods sold $ 43 $ 69 Sales and marketing 645 591 Research and development 8 14 General and administrative 578 849 Total $ 1,274 $ 1,523 The above stock-based compensation expense related to the following equity-based awards (in thousands): Three Months Ended March 31, 2023 2022 Stock options $ 825 $ 1,026 RSU 425 497 ESPP 24 — Total $ 1,274 $ 1,523 The Company estimated the fair value of stock options using the Black-Scholes option-pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options was estimated u sing the following weighted-average assumptions: Three Months Ended March 31, 2023 2022 Expected dividends 0 % 0 % Expected volatility 77.8 70.8 % Risk-free interest rate 4.2 % 1.9 % Expected term 6 years 6 years

Net Loss Per Share Attributable

Net Loss Per Share Attributable To Common Stockholders	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	11. Net Loss Per Share Attributable To Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which is computed by dividing the net loss by th e weighted-average number of common stock outstanding for the period. Quarter Ended March 31, (in thousands, except share and per share amounts) 2023 2022 Numerator Net loss attributable to common stockholders $ ( 11,343 ) $ ( 10,925 ) Denominator: Weighted-average common stock outstanding 96,573,894 28,480,745 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.12 ) $ ( 0.38 ) The following table indicates the number of potentially dilutive securities excluded from the calculation of Diluted net income (loss) per common share because their inclusion would have been anti-dilutive. The number of shares is as of the end of each period: Three Months Ended March 31, 2023 2022 Common stock warrants 77,842 77,842 Unvested early exercised common stock options 140,413 311,836 Options to purchase common stock 27,056,747 2,179,647 Unvested restricted stock units 871,792 390,750

Employee Benefit Plan

Employee Benefit Plan	3 Months Ended
	Mar. 31, 2023
Disclosure Text Block Supplement [Abstract]
Employee Benefit Plan	12. Employee Benefit Plan In 2012, the Company implemented a tax deferred savings plan, commonly referred to as a 401(k) plan. Employee contributions are withheld from standard payroll checks and are automatically withdrawn from the Company checking account and deposited into individual employee retirement accounts a few days following each payroll period. There has been no Company matching of employee contributions to the plan through March 31, 2023 .

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events Second Hologic Action and First Minerva Action On April 19, 2023, Hologic and the Company entered into a settlement agreement resolving all claims associated with their outstanding litigations, see disclosure at Note 8.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (GAAP). Certain prior year amounts have been reclassified to conform to the current year presentation.
Unaudited interim financial information	Unaudited interim financial information The accompanying condensed balance sheet as of March 31, 2023, the condensed statements of operations, the condensed statements of stockholders’ equity and condensed statements of cash flows for the periods ended March 31, 2023 and 2022 are unaudited. The unaudited interim condensed financial statements have been prepared on the same basis as the 2022 audited annual financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2023 and the results of its operations and its cash flows for the three-month periods ended March 31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three-month periods ended March 31, 2023 and 2022 are also unaudited. The results for the three-month period ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods, or any future year or period. The balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. Certain disclosures have been condensed or omitted from the interim condensed financial statements. These unaudited interim condensed financial statements should be read in conjunction with the audited annual financial statements and related notes. The significant accounting policies used in the preparation of the unaudited condensed financial statements for the three-month periods ended March 31, 2023 and 2022, are consistent with those discussed in Note 2 to the audited financial statements and notes thereto for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC) on March 22, 2023. There have been no significant changes in the significant accounting policies or critical accounting estimates since December 31, 2022, except for the accounting policy related to FASB Accounting Standards Update (ASU) 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments discussed below.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Significant estimates and assumptions include accounts receivable allowances, inventory allowances, recoverability of long-term assets, including definite-lived intangible assets, revaluation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, contingent consideration liability, valuation of the redeemable convertible preferred stock warrant liability and derivative liabilities, deferred tax assets and related valuation allowances, impact of contingencies and the Company’s incremental borrowing rate used to calculate lease assets .
Change in Accounting Estimate	Change in accounting estimate In accordance with our policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis. This review, which included a study of historic replacement requirements, indicated that the actual lives of equipment under customer usage agreements were longer than the estimated useful lives used for depreciation purposes. As a result, effective January 1, 2023, the Company changed its estimate of the useful lives of equipment under customer usage agreements from three to five years . The effect of this change in estimate was to reduce depreciation expense by $ 0.3 million, decrease net loss by $ 0.3 million and decrease basic and diluted loss per share by an immaterial amount, for the three months ended March 31, 2023.
Fair value of financial instruments	Fair value of financial instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their fair value due to the short-term nature of these assets and liabilities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates its fair value and is classified as a Level 2 liability.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (FDIC) insured limits. The Company earns revenue from sale of disposable devices and controllers to customers such as hospitals, ambulatory surgical centers and physician offices. The Company’s accounts receivable are derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral from its customers. At March 31, 2023 and 2022, and for the periods then ended, no customer accounted for more than 10.0% of accounts receivable or revenue.
Concentration of suppliers	Concentration of suppliers The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect our results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event.
Accounts Receivable and Estimated Credit Losses	Accounts Receivable and Estimated Credit Losses The Company adopted ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , effective January 1, 2023 using the modified retrospective method. The adoption of this standard did not have a material cumulative effect on opening accumulated deficit as of January 1, 2023 and did not have a material impact on the Company’s financial statements for the three months ended March 31, 2023. As of January 1, 2023, accounts receivable are recorded at invoice value, net of the Company's reserve for estimated credit losses. The Company applies its loss-rate method to measure its estimated credit loss for receivables using its historical collection experience, current and ongoing evaluation of customer balances including transaction history, aging status and financial condition of its customers, plus reasonable and supportable forecast of future economic market conditions. Specific credit loss reserve amounts are established to record the appropriate reserve for the Company's current estimate of credit losses (CECL) reserves for its pool of identified customers that have an identified risk of default. A general credit loss reserve is then established based upon the Company’s assessment of estimated credit losses for its remaining receivables pool based on its loss-rate method. Balances are written-off when they are ultimately determined to be uncollectible. The following table summarizes the activity in the reserve for credit loss account (in thousands): January 1, 2023 $ 542 Amounts charged (reversed) to costs and expenses ( 1 ) Write-offs ( 26 ) March 31, 2023 $ 515
Advertising costs	Advertising costs Expenses related to advertising of products are charged to sales and marketing expense as incurred. During the three months ended March 31, 2023, the Company incurred $ 0.1 million in advertising expenses. The Company did no t have any material advertising expenses during the three months ended March 31, 2022.
Net loss per share	Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, , redeemable convertible preferred stock warrants, convertible notes, common stock subject to repurchase, restricted stock units and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss per share is presented. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. Because the Company has reported a net loss for the three-month periods ended March 31, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for all periods presented.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule Of Reserve For Credit Loss Account	The following table summarizes the activity in the reserve for credit loss account (in thousands): January 1, 2023 $ 542 Amounts charged (reversed) to costs and expenses ( 1 ) Write-offs ( 26 ) March 31, 2023 $ 515

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	Disaggregation of revenue For the Three Months Ended March 31, 2023 2022 Minerva ES 45.2 % 44.0 % Genesys HTA 27.8 % 30.3 % Symphion 26.3 % 25.1 % Other 0.7 % 0.6 % 100.0 % 100 %
Schedule of Contract Balance	The Compan y’s contract balances consist of the following (in thousands): March 31, December 31, 2023 2022 Accounts receivable, net $ 7,392 $ 7,244 Contract liability—current (see Note 6) $ 581 $ 339

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): March 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 20,687 $ — $ — $ 20,687 Total financial assets $ 20,687 $ — $ — $ 20,687 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 3,149 $ — $ — $ 3,149 Total financial assets $ 3,149 $ — $ — $ 3,149
Schedule of Change in Fair Value of the Contingent Consideration Liability	The change in fair value of the contingent consideration liability is summarized below (in thousands): Contingent Fair value, December 31, 2021 $ 14,094 Change in fair value ( 151 ) Payment ( 5,000 ) Ending fair value, March 31, 2022 $ 8,943

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2023
Balance Sheet Components [Abstract]
Schedule of Cash and Cash Equivalents	The Company’s cash and cash equivalents consist of the following (in thousands): March 31, December 31, 2023 2022 Cash $ 4,568 $ 3,793 Cash equivalents: Money market funds 20,687 3,149 Total cash and cash equivalents $ 25,255 $ 6,942
Schedule of Inventory	Inventory consists of the following (in thousands): March 31, December 31, 2023 2022 Finished goods $ 7,295 $ 7,142 Component materials 9,900 9,708 Total inventory $ 17,195 $ 16,850
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, 2023 2022 Prepaid expenses $ 2,465 $ 2,164 Prepaid insurance 1,009 1,560 Other current assets 191 755 Total prepaid expenses and other current assets $ 3,665 $ 4,479
Property and Equipment, Net	Property and equipment, net consist of th e following (in thousands): March 31, December 31, Useful life (years) 2023 2022 Computers and software 2 $ 398 $ 343 Machinery and equipment 3 667 664 Furniture and fixtures 7 48 48 Tools and dies 2 901 900 Construction in progress — 88 131 Equipment under customer usage agreements 5 13,733 13,226 Leasehold improvements Lesser of useful life or lease term 155 155 15,990 15,467 Less: accumulated depreciation and amortization ( 10,615 ) ( 10,425 ) Property and equipment, net $ 5,375 $ 5,042
Schedule of Intangible Assets, Net	Intangible asset, net con sist of the following (in thousands): March 31, 2023 Remaining life (years) Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks 3.7 $ 3,969 $ ( 1,756 ) $ 2,213 Developed technology 0.2 30,819 ( 8,860 ) 21,959 Customer relationships 7.2 13,466 ( 12,905 ) 561 Total intangible assets $ 48,254 $ ( 23,521 ) $ 24,733 December 31, 2022 Remaining life (years) Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks 3.9 $ 3,969 $ ( 1,603 ) $ 2,366 Developed technology 0.4 30,819 ( 8,090 ) 22,729 Customer relationships 7.4 13,466 ( 11,783 ) 1,683 Total intangible assets $ 48,254 $ ( 21,476 ) $ 26,778
Schedule of Future Amortization Expense of Intangible Assets Related to Acqusition of Assets	Future amortization expense of intangible assets related to the acquisition of assets from Boston Scientific Corporation (BSC) as of March 31, 2023 is as follows (in thousands): 2023 (remaining nine months) $ 3,331 2024 3,693 2025 3,693 2026 3,614 2027 3,082 Thereafter 7,320 Total $ 24,733
Schedule of Accrued Compensation	Accrued compensation consists of the following (in thousands): March 31, December 31, 2023 2022 Accrued vacation $ 1,550 $ 1,559 Accrued bonuses 651 1,248 Accrued commissions 843 730 Other accrued personnel related expenses 98 164 Total accrued compensation $ 3,142 $ 3,701
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in th ousands): March 31, December 31, 2023 2022 Accrual for litigation $ 2,000 $ 2,000 Accrued professional fees 400 643 Accrued sales and use taxes 339 271 Accrual for inventory in transit - 663 Contract liability 581 339 Accrued interest expense 339 321 Others 1,064 1,287 Total accrued liabilities $ 4,723 $ 5,524

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt	The CIBC Loan consists of the following (in thousands): March 31, December 31, 2023 2022 Term loan principal $ 40,000 $ 40,000 Less: Debt discount and debt issuance cost ( 601 ) ( 665 ) Accrued interest 339 321 Term loan $ 39,738 $ 39,656
Schedule of Contractual Maturities of Financing Obligations	As of March 31, 2023, the aggregate future payments under the CIBC Loan (including interest payments) are as follows (in thousands): 2023 (remaining nine months) $ 5,650 2024 16,323 2025 14,958 2026 12,508 Total 49,439 Less: unamortized debt discounts and issuance costs ( 601 ) Less: interest ( 9,100 ) Term loan $ 39,738

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Summary of Lease Costs	The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the three -month periods ended March 31, 2023 and 2022: For Three Months Ended Lease Cost (in thousands) Operating lease cost $ 163 Variable lease cost — Total lease cost $ 163 Other Information Operating cash flows used for lease liabilities $ 212 Right of use asset acquired under operating lease on the adoption of ASC 842 $ 109 Weighted average remaining lease term (in years) 0.2 Weighted average incremental borrowing rate 4.0 %
Schedule of Maturities of Operating Lease Liabilities	The maturities of the operating lease liabilities were as follows (in thousands): March 31, 2023 2023 minimum payments $ 143 Total undiscounted lease payments 143 Less: imputed interest — Total operating lease liability, current maturities $ 143
Schedule of Future Minimum Rental Payments for Operating Leases	The future minimum lease payments under all non-cancelable operating lease obligations as of March 31, 2023 were as follows (in thousands): 2023 (remaining two months) $ 143 Total minimum lease payments $ 143

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of common stock warrants	Common stock warrants As of March 31, 2023, the Company`s outstanding warrants to purchase shares of common stock, consisted of the following: Issuance Date Number of Shares of Common Stock Issuable Exercise Price Classification Expiration Date May 9, 2017 33,964 $ 11.31 Equity May 8, 2027 July 19, 2019 43,878 $ 11.31 Equity July 18, 2029 77,842
Schedule of Shares Reserved for Future Issuance	The Company has shares of common stock reserved for future issuances as follows: March 31, December 31, 2023 2022 Warrants to purchase common stock 77,842 77,842 Common stock options issued and outstanding 27,056,747 2,290,596 Common stock available for future grants 13,557,722 374,099 Restricted stock units issued and outstanding 871,792 1,247,059 Common stock available for ESPP 3,541,141 62
Schedule of Stock Option Activity	A summar y of stock option activity is set forth below (in thousands, except share and per share data): Number of Weighted Weighted Aggregate Outstanding, December 31, 2022 2,290,596 $ 8.33 8.0 $ 1 Options granted 24,921,277 $ 0.28 Options exercised ( 6 ) $ 0.61 Options forfeited or cancelled ( 155,120 ) $ 7.32 Outstanding, March 31, 2023 27,056,747 $ 0.92 9.7 $ 1 Shares exercisable March 31, 2023 1,506,339 $ 8.86 6.0 $ - Vested and expected to vest, March 31, 2023 27,056,747 $ 0.92 9.7 $ 1
Schedule of Restricted Stock Units	A summary of RSU activity is s et forth below: Number of Weighted Average Grant Date Fair Value Unvested, December 31, 2022 1,247,059 $ 2.58 Released ( 356,487 ) $ 2.58 Forfeited or cancelled ( 18,780 ) $ 2.63 Unvested, March 31, 2023 871,792 $ 2.58
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended March 31, 2023 2022 Cost of goods sold $ 43 $ 69 Sales and marketing 645 591 Research and development 8 14 General and administrative 578 849 Total $ 1,274 $ 1,523 The above stock-based compensation expense related to the following equity-based awards (in thousands): Three Months Ended March 31, 2023 2022 Stock options $ 825 $ 1,026 RSU 425 497 ESPP 24 — Total $ 1,274 $ 1,523
Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions	The fair value of stock options was estimated u sing the following weighted-average assumptions: Three Months Ended March 31, 2023 2022 Expected dividends 0 % 0 % Expected volatility 77.8 70.8 % Risk-free interest rate 4.2 % 1.9 % Expected term 6 years 6 years

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable To Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which is computed by dividing the net loss by th e weighted-average number of common stock outstanding for the period. Quarter Ended March 31, (in thousands, except share and per share amounts) 2023 2022 Numerator Net loss attributable to common stockholders $ ( 11,343 ) $ ( 10,925 ) Denominator: Weighted-average common stock outstanding 96,573,894 28,480,745 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.12 ) $ ( 0.38 )
Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding	The following table indicates the number of potentially dilutive securities excluded from the calculation of Diluted net income (loss) per common share because their inclusion would have been anti-dilutive. The number of shares is as of the end of each period: Three Months Ended March 31, 2023 2022 Common stock warrants 77,842 77,842 Unvested early exercised common stock options 140,413 311,836 Options to purchase common stock 27,056,747 2,179,647 Unvested restricted stock units 871,792 390,750

Formation and Business of the_2

Formation and Business of the Company - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Feb. 09, 2023	Dec. 27, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net Loss			$ 11,343	$ 10,925
Accumulated deficit			(294,856)		$ (283,668)
Cash and cash equivalents			$ 25,255		$ 6,942
Common stock, par value			$ 0.001		$ 0.001
Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Gross proceeds of private placement	$ 30,000
Private placement agent fees and offering expenses	$ 3,200
Purchasers | Purchase Agreement | Private placement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate number of shares agreed to be sold		146,627,565
Common stock, par value		$ 0.001
Purchase price per share		$ 0.2046
Premium Percentage		25%
Volume Weighted Average Price Trailing Period		5 days

Summary of significant accoun_4

Summary of significant accounting policies - Additional Information (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) Customer $ / shares	Mar. 31, 2022 USD ($) Customer $ / shares
Financing Receivable Impaired [Line Items]
Number of customer accounted for accounts receivable or revenue | Customer	0	0
Advertising expenses	$ 100	$ 0
Decrease net loss	(11,343)	(10,925)
Improve in operating loss	$ (10,310)	$ (10,300)
Improve in loss per share | $ / shares	$ (0.12)	$ (0.38)
Customer Usage Agreements
Financing Receivable Impaired [Line Items]
Decrease in depreciation expense	$ 300
Decrease net loss	$ 300
Customer Usage Agreements | Maximum
Financing Receivable Impaired [Line Items]
Property and equipment, useful life	5 years
Customer Usage Agreements | Minimum
Financing Receivable Impaired [Line Items]
Property and equipment, useful life	3 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule Of Reserve For Credit Loss Account (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Beginnning balance	$ 542
Amounts charged (reversed) to costs and expenses	(1)
Write-offs	(26)
Ending balance	$ 515

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings	$ (294,856)		$ (283,668)
ASU 2016 -13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date		Jan. 01, 2023
Derecognized in allowance for doubtful accounts		$ 700
CECL reserve		500
ASU 2016 -13 | Cumulative Effect Period Of Adoption Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings		$ 200

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	100%	100%
Minerva ES
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	45.20%	44%
Genesys HTA
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	27.80%	30.30%
Symphion
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	26.30%	25.10%
Other
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	0.70%	0.60%

Revenue - Additional Informatio

Revenue - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Percentage of revenue subject to point-in-time recognition	100%	99.40%
Percentage of revenue on sale of extended warranties on capital equipment	0.10%	1%
Percentage of total revenue derived from sale of single-use (disposable) products	98.30%	97%

Revenue - Schedule of Contract

Revenue - Schedule of Contract Balance (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Accounts receivable, net	$ 7,392	$ 7,244
Contract liability-current (see Note 6)	$ 581	$ 339

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Cash equivalents:
Money market funds	$ 20,687	$ 3,149
Total financial assets	20,687	3,149
Level 1
Cash equivalents:
Money market funds	20,687	3,149
Total financial assets	$ 20,687	$ 3,149

Fair Value - Summary of Changes

Fair Value - Summary of Changes in Fair Value of the Contingent consideration Liability (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning fair value	$ 14,094
Change in fair value	(151)
Payment	(5,000)
Ending fair value	$ 8,943

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Components [Abstract]
Cash	$ 4,568	$ 3,793
Cash equivalents:
Money market funds	20,687	3,149
Total cash and cash equivalents	$ 25,255	$ 6,942

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Components [Abstract]
Finished goods	$ 7,295	$ 7,142
Component materials	9,900	9,708
Total inventory	$ 17,195	$ 16,850

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Components [Abstract]
Prepaid expenses	$ 2,465	$ 2,164
Prepaid insurance	1,009	1,560
Other current assets	191	755
Total prepaid expenses and other current assets	$ 3,665	$ 4,479

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 15,990	$ 15,467
Less: accumulated depreciation and amortization	(10,615)	(10,425)
Property and equipment, net	5,375	5,042
Computer and Software
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 398	343
Property and equipment, useful life	2 years
Machinery and Equipment
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 667	664
Property and equipment, useful life	3 years
Furniture and Fixtures
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 48	48
Property and equipment, useful life	7 years
Tools and Dies
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 901	900
Property and equipment, useful life	2 years
Construction in Progress
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 88	131
Equipment Under Customer Usage Agreements
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 13,733	13,226
Property and equipment, useful life	5 years
Leasehold Improvements
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 155	$ 155
Property and equipment, useful life, description	Lesser of useful life or lease term

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Balance Sheet Components [Line Items]
Depreciation and amortization expense on property and equipment	$ 0.5	$ 0.6
Amortization expense on intangible assets	2	2
Inventory in transit and recognized into accounts payable	0.7
Customer Usage Agreements
Balance Sheet Components [Line Items]
Decrease in depreciation expense	0.3
Equipment Under Customer Usage Agreements
Balance Sheet Components [Line Items]
Depreciation and amortization expense on property and equipment	$ 0.4	$ 0.6

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Intangible Asset, Net (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Components [Line Items]
Gross Carrying Value	$ 48,254	$ 48,254
Accumulated Amortization	(23,521)	(21,476)
Net Carrying Value	24,733	26,778
Trademarks
Balance Sheet Components [Line Items]
Gross Carrying Value	3,969	3,969
Accumulated Amortization	(1,756)	(1,603)
Net Carrying Value	$ 2,213	$ 2,366
Remaining life (years)	3 years 8 months 12 days	3 years 10 months 24 days
Developed Technology
Balance Sheet Components [Line Items]
Gross Carrying Value	$ 30,819	$ 30,819
Accumulated Amortization	(8,860)	(8,090)
Net Carrying Value	$ 21,959	$ 22,729
Remaining life (years)	2 months 12 days	4 months 24 days
Customer Relationships
Balance Sheet Components [Line Items]
Gross Carrying Value	$ 13,466	$ 13,466
Accumulated Amortization	(12,905)	(11,783)
Net Carrying Value	$ 561	$ 1,683
Remaining life (years)	7 years 2 months 12 days	7 years 4 months 24 days

Balance Sheet Components - Sc_5

Balance Sheet Components - Schedule of Future Amortization Expense of Intangible Assets Related to Acquisition of Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Components [Abstract]
2023 (remaining nine months)	$ 3,331
2024	3,693
2025	3,693
2026	3,614
2027	3,082
Thereafter	7,320
Net Carrying Value	$ 24,733	$ 26,778

Balance Sheet Components - Sc_6

Balance Sheet Components - Schedule of Accrued Compensation (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Components [Abstract]
Accrued vacation	$ 1,550	$ 1,559
Accrued bonuses	651	1,248
Accrued commissions	843	730
Other accrued personnel related expenses	98	164
Total accrued compensation	$ 3,142	$ 3,701

Balance Sheet Components - Sc_7

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Components [Abstract]
Accrual for litigation	$ 2,000	$ 2,000
Accrued professional fees	400	643
Accrued sales and use taxes	339	271
Accrual for inventory in transit		663
Contract liability	581	339
Accrued interest expense	339	321
Others	1,064	1,287
Total accrued liabilities	$ 4,723	$ 5,524

Debt - CIBC Term loan - Additio

Debt - CIBC Term loan - Additional Information (Details) - CIBC Term Loan - USD ($) $ in Thousands		3 Months Ended
	Oct. 08, 2021	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2022
Debt Instrument [Line Items]
Debt financing	$ 40,000	$ 40,000			$ 40,000
Debt instrument effective interest rate		11.90%
Payments of loan costs	$ 1,000
Interest Expense related to debt discount , debt issuance costs and exit fees			$ 100
Interest expense on debt		$ 1,100		$ 600

Debt - CIBC Term Loan - Schedul

Debt - CIBC Term Loan - Schedule of Debt (Details) - CIBC Term Loan - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Oct. 08, 2021
Debt Instrument [Line Items]
Term loan principal	$ 40,000	$ 40,000	$ 40,000
Less: Debt discount and debt issuance cost	(601)	(665)
Accrued interest	339	321
Term loan	$ 39,738	$ 39,656

Debt - Schedule of Contractual

Debt - Schedule of Contractual Maturities of Financing Obligations (Details) - CIBC Term Loan - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
2023 (remaining nine months)	$ 5,650
2024	16,323
2025	14,958
2026	12,508
Total	49,439
Less: unamortized debt discounts and issuance costs	(601)	$ (665)
Less: interest	(9,100)
Term loan	$ 39,738	$ 39,656

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)		3 Months Ended
	Jul. 29, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Loss Contingencies [Line Items]
Operating lease right-of-use asset		$ 109,000		$ 270,000
Operating lease liabilities		$ 100,000
ASC 842
Loss Contingencies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true
Change in Accounting Principle, Accounting Standards Update, Adoption Date		Jan. 01, 2022
Santa Clara
Loss Contingencies [Line Items]
Rent expense recognized		$ 200,000	$ 200,000
California
Loss Contingencies [Line Items]
Lease commencement date	Jun. 01, 2023
Lease expiration date	May 31, 2028
Base rent payments	$ 88,341
Incremental annual rental payment percentage	3%
Mission Park
Loss Contingencies [Line Items]
Letters of credit	$ 300,000
Office Leases | Santa Clara
Loss Contingencies [Line Items]
Letters of credit		$ 500,000		$ 500,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Lease Cost
Operating lease cost	$ 163
Total lease cost	163
Other Information
Operating cash flows used for lease liabilities	212
Right of use asset acquired under operating lease on the adoption of ASC 842	$ 109	$ 270
Weighted average remaining lease term (in years)	2 months 12 days
Weighted average incremental borrowing rate	4%

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
2023 minimum payments	$ 143
Total undiscounted lease payments	143
Total operating lease liability, current maturities	$ 143	$ 355

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023 (remaining two months)	$ 143
Total minimum lease payments	$ 143

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Dec. 27, 2022	Dec. 01, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized			300,000,000		100,000,000
Common stock, par value			$ 0.001		$ 0.001
Fair value of options vested			$ 800	$ 1,000
Weighted average grant date fair value			$ 0.20	$ 3.50
Unrecognized stock-based compensation expense			$ 8,600
Unrecognized stock-based compensation expense, weighted-average recognition period			3 years 3 months 18 days
Repurchase of common stock			0	0
Shares subject to repurchase			140,413		188,025
Aggregate amounts of not yet vested early stock			$ 100		$ 100
Preferred stock, shares authorized			15,000,000		5,000,000
Preferred stock, par value			$ 0.001		$ 0.001
Risk-free interest rate			4.20%	1.90%
Dividend rate			0%	0%
Expected term			6 years	6 years
Volatility			77.80%	70.80%
Compensation expense			$ 1,274	$ 1,523
ESPP
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense, weighted-average recognition period			6 months
Restricted Stock Units
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense			$ 1,700
Unrecognized stock-based compensation expense, weighted-average recognition period			2 years 9 months 18 days
Compensation expense			$ 425	$ 497
Tranche One | ESPP
Subsidiary or Equity Method Investee [Line Items]
Risk-free interest rate		4.61%
Dividend rate		0%
Expected term		6 months
Volatility		77.21%
Tranche Two | ESPP
Subsidiary or Equity Method Investee [Line Items]
Risk-free interest rate		4.61%
Dividend rate		0%
Expected term		1 year
Volatility		76.29%
Purchasers | Purchase Agreement | Private placement
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value	$ 0.001
Aggregate number of shares agreed to be sold	146,627,565
Maximum | ESPP
Subsidiary or Equity Method Investee [Line Items]
Compensation expense			$ 100

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock Warrants (Details) - $ / shares	Jul. 19, 2019	May 09, 2017	Mar. 31, 2023
Equity [Abstract]
Issuance Date	Jul. 19, 2019	May 09, 2017
Number of Shares of Common Stock Issuable	43,878	33,964	77,842
Exercise Price	$ 11.31	$ 11.31
Classification	Equity	Equity
Expiration Date	Jul. 18, 2029	May 08, 2027

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Shares Reserved for Future Issuance (Details) - shares	Mar. 31, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Warrants to purchase common stock	77,842	77,842
Common stock options issued and outstanding	27,056,747	2,290,596
Common stock available for future grants	13,557,722	374,099
Restricted stock units issued and outstanding	871,792	1,247,059
ESPP
Class Of Stock [Line Items]
Common stock available for future grants	3,541,141	62

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Number of Shares Underlying Outstanding Options, Beginning balance	2,290,596
Number of Shares Underlying Outstanding Options, Granted	24,921,277
Number of Shares Underlying Outstanding Options, Exercised	(6)
Number of Shares Underlying Outstanding Options, Forfeited or Cancelled	(155,120)
Number of Shares Underlying Outstanding Options, Ending balance	27,056,747	2,290,596
Number of Shares Underlying Outstanding Options, Shares Exercisable	1,506,339
Number of Shares Underlying Outstanding Options, Vested and Expected to Vest	27,056,747
Weighted Average Exercise Price, Outstanding beginning balance	$ 8.33
Weighted Average Exercise Price, Options granted	0.28
Weighted Average Exercise Price, Options exercised	0.61
Weighted Average Exercise Price, Options forfeited or cancelled	7.32
Weighted Average Exercise Price, Outstanding ending balance	0.92	$ 8.33
Weighted Average Exercise Price, Shares exercisable	8.86
Weighted Average Exercise Price, vested and expected to vest	$ 0.92
Weighted Average Remaining Contractual Term (in years), Outstanding	9 years 8 months 12 days	8 years
Weighted Average Remaining Contractual Term (in years), Shares exercisable	6 years
Weighted Average Remaining Contractual Term (in years), Vested and Expected to Vest	9 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 1	$ 1
Aggregate Intrinsic Value, Vested and expected to vest	$ 1

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Restricted Stock Units (Details) - Restricted Stock Units	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Underlying Outstanding Restricted Stock, Unvested, Beginning balance | shares	1,247,059
Number of Shares Underlying Outstanding Restricted Stock, Released | shares	(356,487)
Number of Shares Underlying Outstanding Restricted Stock, Forfeited or cancelled | shares	(18,780)
Number of Shares Underlying Outstanding Restricted Stock, Unvested, Ending Balance | shares	871,792
Weighted Average Grant Date Fair Value, Unvested, Beginning balance | $ / shares	$ 2.58
Weighted Average Grant Date Fair Value, Unvested, Released | $ / shares	2.58
Weighted Average Grant Date Fair Value, Unvested, Forfeited or Cancelled | $ / shares	2.63
Weighted Average Grant Date Fair Value, Unvested, Ending Balance | $ / shares	$ 2.58

Stockholders' Equity -Summary o

Stockholders' Equity -Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Class Of Stock [Line Items]
Stock-based compensation expense	$ 1,274	$ 1,523
Cost of Goods Sold
Class Of Stock [Line Items]
Stock-based compensation expense	43	69
Sales and Marketing
Class Of Stock [Line Items]
Stock-based compensation expense	645	591
Research and Development
Class Of Stock [Line Items]
Stock-based compensation expense	8	14
General and Administrative
Class Of Stock [Line Items]
Stock-based compensation expense	578	849
Stock Options
Class Of Stock [Line Items]
Stock-based compensation expense	825	1,026
Restricted Stock Units
Class Of Stock [Line Items]
Stock-based compensation expense	425	$ 497
ESPP
Class Of Stock [Line Items]
Stock-based compensation expense	$ 24

Stockholders' Equity -Schedule

Stockholders' Equity -Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0%	0%
Expected volatility	77.80%	70.80%
Risk-free interest rate	4.20%	1.90%
Expected term	6 years	6 years

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator
Net loss	$ (11,343)	$ (10,925)
Denominator:
Weighted-average common stock outstanding	96,573,894	28,480,745
Net loss per share attributable to common stockholders, basic	$ (0.12)	$ (0.38)
Net loss per share attributable to common stockholders, diluted	$ (0.12)	$ (0.38)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	77,842	77,842
Unvested Early Exercised Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	140,413	311,836
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	27,056,747	2,179,647
Unvested Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	871,792	390,750